Inhibitor Therapeutics heads into the final days of April with a quietly unusual setup: short interest has collapsed to near-zero, yet the cost to borrow has more than doubled over the past year — a combination that tells its own story about a thinly traded OTC biotech.
The dominant move over the past month has been a sharp retreat from short sellers. Estimated short interest fell 45% over the past week, dropping from roughly 22,500 shares to just 11,616 — representing a negligible 0.007% of the free float. For context, the share count reached a recent high above 25,000 in early March before steadily unwinding. With FINRA's official fortnightly settlement data recording only 632 shares short as of April 15, the actual bearish positioning here is de minimis. Availability stands at 9,999% of short interest — every meaningful metric points to an effectively empty borrow book.
That said, the borrow market is not without its own interest. Cost to borrow has more than doubled from roughly 5% last April to 12.3% now, after a sharp step-change at the start of 2026. Relative to the near-zero share volume actually being borrowed, that elevated rate is more a structural artefact of the stock's illiquidity than a signal of squeeze pressure. Availability has collapsed in absolute terms — from a 52-week high utilisation reading of 68% last year to zero today — meaning shorts that existed earlier in the year have almost entirely exited the lending pool.
Price action tells a more optimistic story in the near term. The stock gained 8.8% on the week to close at $0.09, adding to a modest 3% gain over the past month. Two of the most recent earnings-adjacent moves were notably sharp: a 37.5% jump on March 27, which faded to a 5-day gain of -11%, and an 11.4% single-day move on March 26 that held. The April 13 event produced a 1-day drop of 7.5% before recovering to a 5-day gain of 12.25% — suggesting the stock can swing hard in both directions around catalysts.
Ownership is highly concentrated. The top two holders — James Donovan and Ronald Osman — together control roughly 30% of the company, with Blackrobe Capital Partners holding a further 11.6% and MOAB Investments at 6.1%. The holder count stands at just 12 in the institutional table, underscoring the thin, closely held nature of the register. Insider data is too stale (last recorded trade in December 2019) to be meaningful as a current signal.
Factor scores add one note of nuance. The utilisation rank sits at the 92nd percentile — high relative to the universe — even though absolute utilisation has fallen to zero. That apparent contradiction reflects how the rank compares historical peaks rather than current levels. The ORTEX short score of 31.8 has eased from 32.9 at the end of March, consistent with the decline in short positioning. With no confirmed upcoming earnings event and price data now six days stale, the key variable to watch is whether any fresh catalyst — a pipeline update or regulatory filing — reactivates the kind of single-day volatility the stock has repeatedly demonstrated.
See the live data behind this article on ORTEX.
Open INTI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
